Filtered By:
Management: Marketing
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Elevian Announces $15 Million Equity Financing
Company Expands Leadership Team as it Advances Preclinical Studies of rGDF11 in Stroke and Other Age-Related Diseases
ALLSTON, Mass., Nov. 24, 2020 -- (Healthcare Sales & Marketing Network) -- Elevian, an emerging biotech company developing medicines t... Biopharmaceuticals, Regenerative Medicine, Venture Capital Elevian, age-related disease, GDF11
Source: HSMN NewsFeed - November 24, 2020 Category: Pharmaceuticals Source Type: news
MIVI Neuroscience Secures Series B Funding
EDEN PRAIRIE, Minn., Jan. 21, 2021 -- (Healthcare Sales & Marketing Network) -- MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, today announced the closing of its Series B funding including ... Devices, Interventional, Neurology, Venture Capital MIVI Neuroscience, Q Aspiration System, DAISe , Thrombectomy
Source: HSMN NewsFeed - January 21, 2021 Category: Pharmaceuticals Source Type: news
Neurolutions IpsiHand Upper Extremity Rehabilitation System
U.S. FDA authorizes marketing of Neurolutions IpsiHand Upper Extremity Rehabilitation System to facilitate muscle rehabilitation in stroke patients
Source: Disabled World - April 24, 2021 Category: Disability Tags: FDA Approvals Source Type: news
City Heat is Worse if You ’re Not Rich or White. The World’s First Heat Officer Wants to Change That
Jane Gilbert knows she doesn’t get the worst of the sticky heat and humidity that stifles Miami each summer. She lives in Morningside, a coastal suburb of historically preserved art deco and Mediterranean-style single-family homes. Abundant trees shade the streets and a bay breeze cools residents when they leave their air conditioned cars and homes. “I live in a place of privilege and it’s a beautiful area,” says Gilbert, 58, over Zoom in early June, shortly after beginning her job as the world’s first chief heat officer, in Miami Dade county. “But you don’t have to go far to see t...
Source: TIME: Science - July 7, 2021 Category: Science Authors: Ciara Nugent Tags: Uncategorized climate change feature Londontime Source Type: news
An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular heart chamber beatings. It affects three to six million people in the U.S.1, among whom 85% to 90% are eligible for oral anticoagulation therapies2,3. As established in the literature, it is of great interest to properly choose among non-vitamin K antagonist oral anticoagulants (NOACs). Rivaroxaban and Dabigatran were approved by the U.S. FDA in November 2011 and October 2010, respectively. They were the first two NOACs for preventing stroke for non-valvular AF patients and have been widely used since marketing.
Source: Journal of Clinical Epidemiology - July 13, 2021 Category: Epidemiology Authors: Hao Mei, Jiping Wang, Shuangge Ma Source Type: research
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA safety warnings and trends in testosterone marketing to physicians
In this study, we found that testosterone marketing efforts such as marketing spending per encounter, quarterly marketing spending per physician, and quarterly number of encounters per physician increased among non-PCPs and urban physicians for 4 quarters following an FDA boxed warning in 2015 on testosterone prescriptions. After the black box warning, off-label testosterone advertisements stopped. This reduction in advertising could have made it more attractive for pharmaceutical companies to increase their marketing spending targeting non-PCPs and physicians in urban areas. Understanding responses of pharmaceutical compa...
Source: The American Journal of Managed Care - April 11, 2022 Category: Health Management Authors: Adeniyi Togun Ashwini Sankar Pinar Karaca-Mandic Source Type: research
Flinn Foundation commits $5.52M to College of Medicine – Phoenix
The gift will establish two research faculty positions and support training to further translational research in cardiovascular diseases, neurosciences and mental health.
April 7, 2022
University Alumni and Development Programflinn-gift-web.jpg
Lauren MacDonnell, a research associate in the Translational Cardiovascular Research Center, processes samples in the TCRC lab.
Sun Belous/College of Medicine – Phoenix Marketing and CommunicationsHealthCollege of Medicine - PhoenixCollege of PharmacyCompassion
Media contact(s)Beth Smith
College of Medicine – Phoenixbhsmith1@arizona.edu602-827-2676TheFlinn Foundation has...
Source: The University of Arizona: Health - April 6, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research
FDA safety warnings and trends in testosterone marketing to physicians
In this study, we found that testosterone marketing efforts such as marketing spending per encounter, quarterly marketing spending per physician, and quarterly number of encounters per physician increased among non-PCPs and urban physicians for 4 quarters following an FDA boxed warning in 2015 on testosterone prescriptions. After the black box warning, off-label testosterone advertisements stopped. This reduction in advertising could have made it more attractive for pharmaceutical companies to increase their marketing spending targeting non-PCPs and physicians in urban areas. Understanding responses of pharmaceutical compa...
Source: The American Journal of Managed Care - April 11, 2022 Category: Health Management Authors: Adeniyi Togun Ashwini Sankar Pinar Karaca-Mandic Source Type: research
Conformal Medical Announces Launch of CONFORM Pivotal Trial
Study to support U.S. FDA approval of the novel CLAAS® implant for left atrial appendage occlusion (LAAO) and stroke prevention
NASHUA, N.H., June 17, 2022 -- (Healthcare Sales & Marketing Network) -- Conformal Medical, Inc., a medical device compa... Devices, Interventional, Cardiology Conformal Medical, CLAAS System, atrial fibrillation, LAAO
Source: HSMN NewsFeed - June 17, 2022 Category: Pharmaceuticals Source Type: news
MicroTransponder Raises $53M, Appoints New CEO
AUSTIN, Texas, June 20, 2022 -- (Healthcare Sales & Marketing Network) -- MicroTransponder®, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment firm. GPG Ventures and Exceller H... Devices, Neurology, Personnel, Venture Capital MicroTransponder, Vivistim, stroke
Source: HSMN NewsFeed - June 20, 2022 Category: Pharmaceuticals Source Type: news
Climate Experts Are Testing New Ways To Reach the People Most Affected by Extreme Heat
As heat waves become longer, hotter, and more widespread across the planet, human responses to them are becoming increasingly local and specialized.
Both scientific researchers and government officials are finding that the best strategies to keep cool are ones that are specially tailored to a community. That may seem obvious, given that outdoor laborers need different cooling resources than school teachers, for instance. But existing national and regional policies aren’t always that fine tuned—and they run the risk of wasting resources or missing the most vulnerable people.
[time-brightcove not-tgx=”tru...
Source: TIME: Health - July 19, 2022 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized climate climate change Climate Is Everything extreme weather healthscienceclimate Source Type: news
Finding the everyday miracles in life
Last week I was writing about what it takes for a miracle to happen and one of my commentators, the lovely Patsy Collins who joined me on the podcast not that long ago, pointed out that there are all sorts of miracles that happen, including some everyday miracles we never know about, because they happen behind the scenes.
And it got me thinking about the all the little miracles that have happened in my life over the years. And, once I got thinking, I got into musing about what life would be like if they hadn’t happened. And, as it’s been a week of ups and downs on the exam front I thought I might as well start ...
Source: The Hysterectomy Association - August 22, 2020 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Life Happiness miracle Source Type: news
